Latest news with #TELABio
Yahoo
2 days ago
- Business
- Yahoo
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units covering 30,000 shares of its common stock to Jim Hagen, the Company's Senior Vice President – Strategic Commercial Operations, with a grant date of June 2, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Mr. Hagen's employment compensation and were granted as an inducement material to his acceptance of employment with TELA Bio. The stock options have an exercise price equal to $1.42 per share, the closing price of TELA Bio's common stock as reported on the Nasdaq Global Market on the Grant Date. The stock options have a ten-year term and vest over four years, with 25% of the shares underlying the stock option vesting on the first anniversary of the Grant Date and the remaining 75% of the shares vesting in equal monthly installments over 36 months thereafter. The restricted stock units will vest in equal annual installments over four years. The equity awards are subject to Mr. Hagen's continued service with TELA Bio through the applicable vesting dates. About TELA Bio, Inc. TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit Caution Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law. Investor ContactLouisa Smithir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units covering 30,000 shares of its common stock to Jim Hagen, the Company's Senior Vice President – Strategic Commercial Operations, with a grant date of June 2, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Mr. Hagen's employment compensation and were granted as an inducement material to his acceptance of employment with TELA Bio. The stock options have an exercise price equal to $1.42 per share, the closing price of TELA Bio's common stock as reported on the Nasdaq Global Market on the Grant Date. The stock options have a ten-year term and vest over four years, with 25% of the shares underlying the stock option vesting on the first anniversary of the Grant Date and the remaining 75% of the shares vesting in equal monthly installments over 36 months thereafter. The restricted stock units will vest in equal annual installments over four years. The equity awards are subject to Mr. Hagen's continued service with TELA Bio through the applicable vesting dates. About TELA Bio, Inc. TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit Caution Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law. Investor ContactLouisa Smithir@ in to access your portfolio
Yahoo
7 days ago
- Business
- Yahoo
TELA Bio Appoints Jeffrey Blizard as President
Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ('TELA Bio'), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. 'This is an important inflection point for TELA Bio,' said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. 'As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected leader with a track record of scaling businesses and inspiring teams—will amplify our ability to compete and win in a dynamic market. We are confident that this leadership evolution will drive meaningful commercial performance and reinforce our commitment to delivering exceptional value to our customers, partners, and shareholders.' Mr. Blizard joins TELA Bio from Abiomed, a Johnson & Johnson company, where he served as Global Head of Surgical Sales. Under his leadership, the Surgical Division of Abiomed grew substantially over multiple years. In addition, he brings extensive commercial experience from leading medtech companies including Medtronic, Intuitive Surgical, and Boston Scientific. 'TELA Bio has built an extraordinary foundation and a differentiated portfolio that is redefining soft tissue reconstruction,' said Jeffrey Blizard, newly appointed President of TELA Bio. 'I'm thrilled to join a mission-driven team with such momentum and look forward to working alongside our talented leadership and commercial teams to accelerate execution, deepen customer relationships, and scale our impact.' About TELA Bio, Inc. TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit Caution Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend' or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the 'Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law. Investor ContactLouisa Smithir@
News.com.au
29-05-2025
- Business
- News.com.au
Health Check: Aroa's ‘hero' product propels the wound management house back into black
Aroa shares surge 13% after the company's full-year results exceeded guidance New wound management IPO does the rounds for $35 million Inoviq shares vault up to 58% on early cancer light therapy results Kiwi-based wounds management house Aroa Biosurgery (ASX:ARX) has exceeded its recent revenue and earnings guidance, after a robust second half on the back of its 'hero' Myriad product range. Aroa's revenue came in at NZ$84.7 million for the year to March 2025, 23% higher and slightly above the NZ$81-84 million range the company guided to in late April. Normalised earnings before interest tax depreciation and amortisation (ebitda) were NZ$4.2 million, compared with the previous NZ$3.1 million loss. Once again, the number was a tad above the guided range of NZ$2-4 million. Aroa has also guided to current-year revenue of NZ$92-100 million, 10-20% higher year on year, with ebitda of NZ$5-8 million. CEO Brian Ward stresses the company's 'star product' Myriad has been delivering the goods, with sales up 35%. Myriad is used for complex wounds including trauma and lower limb salvage. Sold via Aroa's partner TELA Bio, sales of its hernia and breast reconstruction tool Ovitex rose 22% Sales of the Endoform wound dressing were flat, as expected. Expanding indications Ward said the company would focus on expanding indications for its products, which are biological materials sourced from ovine intestines. This push is being supported by several clinical studies, such as a lower limb salvage study trial that resulted in quick healing with no complications. 'That's quite different to what we have seen with other technologies,' he says. However, Aroa has 'paused' the rollout of its Symphony product, for hard-to-heal wounds such as diabetic ulcers. This is because the company has won inpatient reimbursement in the US, but not coverage for physicians. The company plans a supportive trial to win full reimbursement. 'The rules are changing and only products with randomised, controlled trials will be reimbursed,' Ward says. 'This will take many rivals out of the market.' Aroa has product approvals across 50 countries, but almost all its revenue derives from the US. CFO James Agnew said the US tariff impact on the company was likely to be around NZ$1.5 million, or around 1% of revenue. Because of transfer pricing arrangements between TELA Bio and Aroa's own US entity, that's far less than the blanket 10% rate Uncle Sam levies on NZ goods. New wound play does the IPO rounds Still on wound management, Tetraherix is defying the barren IPO biotech landscape with a $35 million raising to advance its novel tools for applications including tissue healing, bone regeneration and surgical spacing. Invented by chemical engineer and University of Sydney researcher Dr Ali Fathi, the platform-based tech is the world's first 'biostealth fluid matrix'. Supplied in ready-to-use syringes, the polymer is injected into the relevant anatomy and sets to a 'chewing-gum' consistency that can be easily moulded to suit the application. Eventually, the material breaks down into water and carbon dioxide. Pending expected US Food and Drug Approval, the company hopes to bring its first products to market in the first half of 2026. These are for dental applications and bone regeneration and orthopaedic uses. The company also has tools in the pipeline for scar prevention during surgery and a prostate surgery 'spacer' to protect surrounding tissue (such as the rectum) during radiation therapy. Doing the rounds Joint lead managers Morgans and Barrenjoey are undertaking the institution round which closes next Tuesday, with a limited retail offering open until June 17. The company is expected to list in late June. The shares are offered at $2.88 a pop, amounting to a $155 million market cap and a $115 million enterprise value (allowing for cash on hand). The founder of 'cloud' accounting software giant Xero, Rod Drury is a notable investor. Invion lights up on skin cancer trial The developer of photodynamic therapies (PTDs) for cancers, Invion (ASX:IVX) has passed the initial safety test for its phase I/II non-melanoma skin cancer trial, being carried out in Queensland (of course). A safety review committee found no 'adverse events' among the first treated patients, who were administered Invion's candidate INV-043 as an ointment. What's more, 'early indications show an observable reduction in the lesion size after a single treatment cycle'. Clinician feedback shows patients did not experience any pain during the treatment, 'which compares favourably to currently approved PDT treatments.' By combining oxygen and light, PTDs are known to kill malignant cells and shut down tumors. Known about for more than a century, the science is supported by more than 500 trials. That said, it's been an overlooked area of oncology and Invion is the only listed exemplar. Invion now is proceeding to the second stage of the adaptive trial, which involves dose optimalisation. Meanwhile, the safety data will influence the company's upcoming phase I/II trial for ano-genital cancer, in alliance with the Peter MacCallum Cancer Centre. Known for wild movements, Invion shares soared up to 58% this morning. Inoviq share freeze highlights disclosure dilemmas A quirky aspect of clinical results is they are not validated until they are presented in a prestigious peer-reviewed publication, or a conference of luminaries. Typically, a company will post top-line results earlier and this can lead to investor confusion about what's new and what's merely additional info for the boffins. On Monday, the ASX suspended share trading in cancer drug developer Inoviq (ASX:IIQ) and queried why the company's shares soared 25%, from 37 cents on Wednesday May 21, to last Friday's high of 46.5 cents. Inoviq yesterday pointed to an abstract poster presentation for an upcoming American Society of Clinical Oncology (ASCO) conference published online. This outlined 'the background, methods, results and conclusions underpinning the high-level results' of an independent patient validation study of the company's ovarian cancer test. The results of the blood test were 'outstanding', with more than 94% accuracy. Hold the front page! Okay, let it go: the guts of the results were outlined on December 3 last year – and referred to in subsequent ASX disclosures. Inoviq says: 'some shareholders may have missed or misunderstood the significance of and may believe the abstract contains new or better information, which is materially price sensitive.' The company believes that was not the case and did not 'announce' the abstract to the ASX. Fair enough! After all, there's nothing more frustrating than companies hyping up presentations that contain no genuine news. In old tabloid terms it's known as a Bamix job: a beat up. But like all good tabloid yarns, there's a twist: Inoviq will present further trial information that is price sensitive, to the ASCO powwow in Chicago on Sunday. This prezzo is under embargo until that day and Inoviq plans to announce the 'tightly held' information first thing on Monday. In the meantime, it's best the shares remain untradeable.
Yahoo
22-05-2025
- Business
- Yahoo
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference
MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference. TELA's management is scheduled to present at the 2025 Jefferies Global Healthcare Conference at 11:05 am ET on June 5th, 2025. Interested parties can access the live and archived webcast at About TELA Bio, Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit Investor ContactLouisa Smithir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
